Investigating the Clinical Trial Journey and Engagement of Neuroendocrine Tumor Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Neuroendocrine Tumors
- Sponsor
- Power Life Sciences Inc.
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Number of neuroendocrine tumor patients who remain in clinical trial until completion
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
Taking part in clinical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.
This research will admit a wide range of data on the clinical study experience of neuroendocrine tumor patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.
It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future patients with neuroendocrine tumor.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient is at least 18 years of age
- •Diagnosis of neuroendocrine tumor
- •Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria
- •Enrolled in another research study
- •Patients with psychiatric illness/social situations that would limit compliance with study requirements
- •Pregnant or lactating woman
Outcomes
Primary Outcomes
Number of neuroendocrine tumor patients who remain in clinical trial until completion
Time Frame: 12 months
Rate of patients who decide to join in a neuroendocrine tumor clinical research
Time Frame: 3 months